Patient demographics
| Variables . | Categories . | MTX (N = 322) . | MMF (N = 414) . | PTCy (N = 44) . | Total (N = 780) . |
|---|---|---|---|---|---|
| Recipient age, y | Median (range) | 51.4 (3.3-69.4) | 61.5 (18.2-80.9) | 45.6 (3.0-70.0) | 56.1 (3.0-80.9) |
| Donor age, y | Median (range) | 35.9 (15.8-77.4) | 41.1 (18.1-76.6) | 29.3 (16.4-63.3) | 38.1 (15.8-77.4) |
| Gender, n (%) | Female | 140 (43) | 185 (45) | 16 (36) | 341 (44) |
| Male | 182 (57) | 229 (55) | 28 (64) | 439 (56) | |
| Disease, n (%) | ALL | 43 (13) | 22 (5) | 12 (27) | 77 (10) |
| AML | 125 (39) | 135 (33) | 20 (45) | 280 (36) | |
| CLL/PLL | 4 (1) | 41 (10) | 0 (0) | 45 (6) | |
| MDS/MPN | 130 (40) | 97 (23) | 9 (20) | 236 (30) | |
| MM/PCL | 6 (2) | 53 (13) | 1 (2) | 60 (8) | |
| NHL/HL | 14 (4) | 66 (16) | 2 (5) | 82 (11) | |
| Conditioning intensity, n (%) | Myeloablative | 303 (94) | 62 (15) | 36 (82) | 401 (51) |
| Nonmyeloablative | 0 (0) | 321 (78) | 4 (9) | 325 (42) | |
| RIC | 19 (6) | 31 (7) | 4 (9) | 54 (7) | |
| Donor CMV serostatus, n (%) | + | 148 (46) | 202 (49) | 22 (50) | 372 (48) |
| − | 174 (54) | 212 (51) | 22 (50) | 408 (52) | |
| Donor relationship, n (%) | Unrelated | 189 (59) | 236 (57) | 35 (80) | 460 (59) |
| Sibling | 133 (41) | 178 (43) | 9 (20) | 320 (41) | |
| Sirolimus, n (%) | No | 322 (100) | 351 (85) | 36 (82) | 709 (91) |
| Yes | 0 (0) | 63 (15) | 8 (18) | 71 (9) | |
| GVHD, n (%) | Acute grade 2-4 | 233 (72) | 254 (61) | 30 (68) | 517 (66) |
| Acute grade 3-4 | 36 (11) | 41 (10) | 1 (2) | 78 (10) | |
| Chronic∗ | 150 (47) | 221 (53) | 14 (32) | 385 (49) |
| Variables . | Categories . | MTX (N = 322) . | MMF (N = 414) . | PTCy (N = 44) . | Total (N = 780) . |
|---|---|---|---|---|---|
| Recipient age, y | Median (range) | 51.4 (3.3-69.4) | 61.5 (18.2-80.9) | 45.6 (3.0-70.0) | 56.1 (3.0-80.9) |
| Donor age, y | Median (range) | 35.9 (15.8-77.4) | 41.1 (18.1-76.6) | 29.3 (16.4-63.3) | 38.1 (15.8-77.4) |
| Gender, n (%) | Female | 140 (43) | 185 (45) | 16 (36) | 341 (44) |
| Male | 182 (57) | 229 (55) | 28 (64) | 439 (56) | |
| Disease, n (%) | ALL | 43 (13) | 22 (5) | 12 (27) | 77 (10) |
| AML | 125 (39) | 135 (33) | 20 (45) | 280 (36) | |
| CLL/PLL | 4 (1) | 41 (10) | 0 (0) | 45 (6) | |
| MDS/MPN | 130 (40) | 97 (23) | 9 (20) | 236 (30) | |
| MM/PCL | 6 (2) | 53 (13) | 1 (2) | 60 (8) | |
| NHL/HL | 14 (4) | 66 (16) | 2 (5) | 82 (11) | |
| Conditioning intensity, n (%) | Myeloablative | 303 (94) | 62 (15) | 36 (82) | 401 (51) |
| Nonmyeloablative | 0 (0) | 321 (78) | 4 (9) | 325 (42) | |
| RIC | 19 (6) | 31 (7) | 4 (9) | 54 (7) | |
| Donor CMV serostatus, n (%) | + | 148 (46) | 202 (49) | 22 (50) | 372 (48) |
| − | 174 (54) | 212 (51) | 22 (50) | 408 (52) | |
| Donor relationship, n (%) | Unrelated | 189 (59) | 236 (57) | 35 (80) | 460 (59) |
| Sibling | 133 (41) | 178 (43) | 9 (20) | 320 (41) | |
| Sirolimus, n (%) | No | 322 (100) | 351 (85) | 36 (82) | 709 (91) |
| Yes | 0 (0) | 63 (15) | 8 (18) | 71 (9) | |
| GVHD, n (%) | Acute grade 2-4 | 233 (72) | 254 (61) | 30 (68) | 517 (66) |
| Acute grade 3-4 | 36 (11) | 41 (10) | 1 (2) | 78 (10) | |
| Chronic∗ | 150 (47) | 221 (53) | 14 (32) | 385 (49) |
ALL, acute lymphoblastic leukemia; AML, acute myeloid leukemia; CLL, chronic lymphocytic leukemia; HL, Hodgkin lymphoma; MDS, myelodysplastic syndrome; MM, multiple myeloma; MPN, myeloproliferative neoplasm; NHL, non-Hodgkin lymphoma; PCL, plasma cell leukemia; PLL, prolymphocytic leukemia; RIC, reduced-intensity conditioning.
National Institutes of Health consensus–defined chronic GVHD10 requiring systemic immunosuppressive treatment or late acute GVHD treated with systemic immunosuppression by 1 year posttransplant.